Santhera Pharmaceuticals Holding AG SANN

Stifel, the broker, has kept its ‘buy’ rating and CHF25 target price on Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0), the Swiss neuromuscular drugmaker, after first-half group revenue doubled to CHF48.3 million. The company left its 2026 guidance of CHF80 million to CHF90 million...

Ad hoc announcement pursuant to Art. 53 LR. A conference call will be held on September 30, 2026, at 14:00 CEST / 13:00 BST / 08:00 EDT. Details are at the end of this news release Strong momentum and expanding global access position AGAMREE® for continued growth Pratteln, Switzerland, September 30, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces the Company’s financial results for the six months ended June 30, 2026. Orlando Oliveira, CEO of Santhera said: “We made strong progress in the f

Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0), the Swiss rare-disease drugmaker, is closing in on a financial turning point, according to research house Edison. In a QuickView note published on Tuesday, analysts Jyoti Prakash and Arron Aatkar said the company was on track to reach...

Pratteln, Switzerland, July 13, 2026 – Santhera Pharmaceuticals (SIX: SANN) today announces an expansion of its exclusive distribution agreement with Biomedica for AGAMREE® (vamorolone), extending the partnership to include Georgia, Kazakhstan, Belarus, Azerbaijan and Uzbekistan, for the treatment of Duchenne muscular dystrophy (DMD) in patients two years of age and older. Biomedica was originally appointed as a distributor for AGAMREE® in October 2025. Under the expanded agreement, Biomedica wi

Data support AGAMREE®’s potential use as a treatment across a broad range of chronic inflammatory rare diseases Pratteln, Switzerland, July 1, 2026 – Santhera Pharmaceuticals (SIX: SANN) today notes topline results from a two-part Phase 1 clinical study of AGAMREE® conducted by its North American licensing partner, Catalyst Pharmaceuticals, Inc. ("Catalyst"). The study suggests that AGAMREE® delivers glucocorticoid and anti-inflammatory activity, while avoiding significant immunosuppressive effe

ROCKVILLE, Md., June 29, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative medicines for areas of significant unmet need, today announced the appointment of Srishti Gupta, MD MPP as Chief Executive Officer and a member of the Company's Board of Directors, effective July 1, 2026. Xi-Yong (Sean) Fu, PhD MBA will step down as Chief Executive Officer to pursue other opportunities. Dr. Fu will

Pratteln, Switzerland, June 2, 2026 – Santhera Pharmaceuticals (SIX: SANN) today notes that AGAMREE has been granted Orphan Drug Designation (ODD) and Global Innovative Products on Fast Track (GIFT) designation by South Korea’s Ministry of Food and Drug Safety (MFDS) for the treatment of Duchenne muscular dystrophy (DMD). These designations recognize the significant unmet medical need among DMD patients in South Korea, where no alternative treatment is currently available. The GIFT designation i

Pratteln, Switzerland, May 26, 2026 – Santhera Pharmaceuticals (SIX: SANN) today announces that its shareholders approved all motions by the Board of Directors at the Annual General Meeting (AGM) held today in Pratteln, Switzerland, with a large majority. Participating shareholders represented a total of 4,838,464 shares or 31.31% of the Company’s share capital. Approval of the 2025 Annual Report and discharge of corporate bodies The shareholders approved the Annual Report, the annual financial

Ad hoc announcement pursuant to Art. 53 LR. Pratteln, Switzerland, May 5, 2026 – Santhera Pharmaceuticals (SIX: SANN) today published the invitation to its Annual General Meeting (AGM), which will be held on May 26, 2026, at 10.00am CEST (doors open at 9:30 am CEST) at the Courtyard Marriott, Hardstrasse 55, 4133 Pratteln, Switzerland. The invitation to the AGM with agenda items and explanations will be sent to registered shareholders by mail and can be viewed on Santhera’s website at https://ww

Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0) nearly doubled revenues to CHF 77.2 million in 2025, driven by strong AGAMREE sales across Europe.  The company expects to hit cash flow breakeven in Q3 2026 without raising additional capital. AOTI Inc (AIM:AOTI) has published a major study showing its wound oxygen therapy healed 64.8% of patients with chronic wounds that had resisted treatment for an average of seven months.  The study, which involved 3,126-patients, also reported hospitalisation rates of just 3.7% and amputation rates of 6.1%. Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF,

Ad hoc announcement pursuant to Art. 53 LR. Pratteln, Switzerland, April 30, 2026 – Santhera Pharmaceuticals (SIX: SANN) proposes to elect Dr. Srishti Gupta, MD, MPP, MPhil, as an Independent Director at the upcoming Annual General Meeting to be held on May 26, 2026. Thomas Meier, Chairman of the Board, said: “Dr. Gupta has a wealth of experience in building and leading successful businesses, and we are delighted she has agreed to be nominated to join the Board. Her depth of experience as a phys

Santhera Pharmaceuticals Holding AG (SPHDF) reports a significant revenue increase and strategic market expansions, despite facing pricing pressures and reimbursement delays.

Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0) CFO Catherine Isted joined Proactive's Stephen Gunnion to discuss a standout 2025, with total revenues almost doubling to CHF 77.2 million — well ahead of guidance — driven by strong AGAMREE sales across Europe and partner contributions from the US and China. European approvals now cover around 80% of major markets, with Spain and Italy the next launches. Long-term data continues to support AGAMREE's differentiated safety profile versus traditional corticosteroids, while a new Asia-Pacific licensing deal and further partnership opportuni

EnergyPathways PLC (AIM:EPP) has launched Front End Engineering and Design for what could become the world's largest compressed air energy storage project. Pre-FEED work with Siemens Energy confirmed the project's viability, with a £15 million financing package now in place to fund the next phase. Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP) has secured FDA Fast Track Designation for its lead cancer drug iSCIB1+ in advanced melanoma. Phase II trial data shows 77% progression-free survival at 20 months, compared with 43% for the current standard of care. Poolbeg Pharma PLC (AIM:POLB, OT

The Swiss rare disease specialist expects to reach breakeven in the third quarter of 2026 without raising additional funds. Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0), the Swiss specialty pharma group listed on the SIX Swiss Exchange, has reconfirmed it expects to reach cash...

Pratteln, Switzerland, April 28, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces that the Board of Directors of the Italian Medicines Agency, AIFA, has approved the reimbursement of AGAMREE® (vamorolone) for the treatment of patients with Duchenne muscular dystrophy (DMD) aged 4 years and older in Italy. AGAMREE is a novel molecule designed to deliver the anti-inflammatory benefits typically associated with glucocorticoids while potentially reducing the risk of adverse effects linked to th

Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 28, 2026, at 14:00 CEST / 13:00 BST / 08:00 EDT. Details are at the end of this news release AGAMREE® delivers strong growth as global expansion accelerates Pratteln, Switzerland, April 28, 2026 – Santhera Pharmaceuticals (SIX: SANN) today announces its full year results for the year ended 31 December 2025. Dario Eklund, CEO of Santhera, said: “Our strong performance in 2025 reflects the continued momentum of AGAM

Pratteln, Switzerland, April 27, 2026 – Santhera Pharmaceuticals (SIX: SANN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending an extension to the marketing authorization for AGAMREE® (vamorolone) to include the treatment of patients with Duchenne muscular dystrophy (DMD) from 2 years of age. AGAMREE is currently approved in the European Union for the treatment of DMD in patients 4 yea